Business Context and Reporting Period
This Form 8-K is filed by Salarius Pharmaceuticals, Inc. (not Decoy Therapeutics Inc.) with a report date of January 13, 2025. The filing discloses preliminary financial condition as of December 31, 2024, and details an unregistered sale of equity securities executed on January 13, 2025.
Key Financial Metrics
- Cash and Cash Equivalents: Approximately $2.4 million as of December 31, 2024 (preliminary, unaudited).
- Capital Raised: $493,500 from the sale of 141,000 common shares at $3.50 per share.
- Revenue, Profit, Margins, Debt: The filing text does not provide clear values for revenue, net income, operating margins, or total debt.
Material Changes and Transactions
The primary material event is the issuance of 141,000 shares of common stock to C/M Capital Master Fund, LP, pursuant to a Securities Purchase Agreement dated December 12, 2024. Additionally, the Company issued 1,410 commitment shares to the investor. The transaction was exempt from registration under Section 4(a)(2) of the Securities Act.
Outlook, Risks, and Management Commentary
- Financial Position: Management notes that the reported cash balance of $2.4 million is preliminary and subject to change upon completion of audited financial statements for the year ended December 31, 2024.
- Disclosure Limitations: The filing explicitly states that additional information is required for a complete understanding of the Company's financial position and results of operations.
- Guidance: No specific forward-looking guidance or operational outlook is provided in this document.
Investor Verification Checklist
- Verify the final audited cash balance for the year ended December 31, 2024, as the $2.4 million figure is preliminary.
- Review the full Securities Purchase Agreement dated December 12, 2024, for terms regarding future purchase obligations or warrants.
- Confirm the total outstanding share count post-issuance to assess dilution impact.
- Check subsequent filings for the Company's audited annual report (Form 10-K) to obtain comprehensive revenue and expense data.